New scan spots hidden thyroid tumors that resist standard treatment
NCT ID NCT04927416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injection of the tracer and undergo a PET/CT scan. The goal is to see how many participants have tumors that light up on the scan, which could guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Gallium-DOTATATE (a radioactive tracer for PET/CT scans)
What this could lead to
If successful, this imaging method could help doctors identify which thyroid cancer patients might benefit from treatments targeting a specific tumor marker (SSTR2).
What could go wrong
This is a small, early-phase imaging study, not a treatment trial. It may not lead to direct patient benefits, and the tracer's ability to improve outcomes is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••